 Nektar Therapeutics NASDAQ:NKTR was upgraded by equities researchers at BidaskClub from a strong sell rating to a sell rating in a research report issued on Saturday, BidAskClub reports. Other equities research analysts have also issued reports about the stock. Oppenheimer reiterated a hold rating and issued a 25.00 price target on shares of Nektar Therapeutics ... 